Manufacturing, Biosimilars and Biobetters

Sandoz and Just – Evotec Biologics Form Biosimilars Pact

May 12, 2023

The new partnership between Sandoz, a Novartis division, and Just – Evotec Biologics will aim to develop and manufacture multiple biosimilars.

Sandoz to Build New Biologics Production Facility in Slovenia

March 17, 2023

Sandoz, a Novartis division, is expected to invest at least $400 million to build a new biologics manufacturing facility in Lendava, Slovenia, to support growing demand for biosimilars.

Method Development for Biosimilar Analysis

June 01, 2022

Linking structure with function is paramount.

Biogen and Xbrane Ink Agreement for Proposed Biosimilar

February 17, 2022

The commercialization and licensing deal will see Biogen commercialize Xbrane’s Xcimzane, a proposed biosimilar for CIMZIA (certolizumab pegol).

Samsung Biologics to Acquire Full Ownership of Samsung Bioepis in $2.3 Billion Deal

January 28, 2022

Samsung Biologics has signed an agreement with Biogen to acquire Biogen’s 50% stake in Samsung Bioepis, a joint venture formed by the two companies, for up to $2.3 billion.

Sandoz Begins Late-Stage Clinical Development for Biosimilar Aflibercept

May 07, 2021

Sandoz will soon begin enrolling patients with neovascular age-related macular degeneration in a Phase III study with its proposed biosimilar to aflibercept.

iBio Supports AzarGen Biotechnologies’ Development of a Rituximab Biosimilar

March 28, 2020

AzarGen’s biosimilar, made in iBio’s plant-based system, will be compared to the original molecule in pre-clinical studies.

Celltrion and Lonza Sign Contract to Manufacture Remsima Drug Substance

September 03, 2019

The partnership will provide cost effective biologics for the world market.

Sandoz in Deal to Commercialize Biosimilar Natalizumab

September 03, 2019

A global agreement with Polpharma Biologics gives Sandoz commercialization rights to a proposed biosimilar natalizumab for relapsing-remitting multiple sclerosis.

Single-Use Bioreactors Unwrap Commercial Manufacturing Options

June 15, 2019

This article provides a review of various 2000-L single-use bioreactors used by biopharmaceutical suppliers for commercial production.